Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | por |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/52571 |
Resumo: | Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil. |
| id |
CRUZ_ac060672924f15ad79658c1db8825860 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/52571 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Rebelatto, Carmen Lúcia KuniyoshiSenegaglia, Alexandra CristinaFranck, Claudio LucianoDaga, Debora ReginaShigunov, PatríciaStimamiglio, Marco AugustoMarsaro, Daniela BoscaroSchaidt, BrunaMicosky, AndressaAzambuja, Ana Paula deLeitão, Cleverson AlexPetterle, Ricardo RasmussenJamur, Valderez RavaglioVaz, Isadora MayMallmann, Antônio PauloCarraro Junior, HipólitoDitzel, EduardoBrofman, Paulo Roberto SludCorrea, Alejandro2022-05-06T18:48:27Z2022-05-06T18:48:27Z2022REBELATTO, Carmen Lúcia Kuniyoshi et al. Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial. Stem Cell Research & Therapy, V. 13, n. 122, p. 1–22, 20221757-6512https://www.arca.fiocruz.br/handle/icict/5257110.1186/s13287-022-02796-1porBMCCOVID-19Postacute sequelaeTerapia CelularMesenchymal Stem CellsSubacute CareCell- and Tissue-Based TherapyCélulas Madre MesenquimatosasAtención SubagudaTratamiento Basado en Trasplante de Células y TejidosCellules souches mésenchymateusesSoins de suiteThérapie cellulaire et tissulaireCélulas-Tronco MesenquimaisCuidados Semi-IntensivosTerapia Baseada em Transplante de Células e TecidosSafety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trialinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlePontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil. / Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Biologia Básica de Células Tronco. Curitiba, PR, Brasil.Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil. / Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Biologia Básica de Células Tronco. Curitiba, PR, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Universidade Federal do Paraná. Setor de Ciências da Saúde, Estatisitica. Curitiba, PR, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil.Hospital e Maternidade Brígida, Curitiba, PR, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Hospital Nossa Senhora do Pilar. Curitiba, PR, Brasil.Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil. / Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Biologia Básica de Células Tronco. Curitiba, PR, Brasil.COVID-19 is a multisystem disease that presents acute and persistent symptoms, the postacute sequelae (PASC). Long-term symptoms may be due to consequences from organ or tissue injury caused by SARSCoV-2, associated clotting or infammatory processes during acute COVID-19. Various strategies are being chosen by clinicians to prevent severe cases of COVID-19; however, a single treatment would not be efcient in treating such a complex disease. Mesenchymal stromal cells (MSCs) are known for their immunomodulatory properties and regeneration ability; therefore, they are a promising tool for treating disorders involving immune dysregulation and extensive tissue damage, as is the case with COVID-19. This study aimed to assess the safety and explore the long-term efcacy of three intravenous doses of UC-MSCs (umbilical cord MSCs) as an adjunctive therapy in the recovery and postacute sequelae reduction caused by COVID-19. To our knowledge, this is one of the few reports that presents the longest follow-up after MSC treatment in COVID-19 patients. This was a phase I/II, prospective, single-center, randomized, double-blind, placebo-controlled clinical trial. Seventeen patients diagnosed with COVID-19 who require intensive care surveillance and invasive mechanical ventilation—critically ill patients—were included. The patient infusion was three doses of 5× 105 cells/kg UC-MSCs, with a dosing interval of 48 h (n=11) or placebo (n=6). The evaluations consisted of a clinical assessment, viral load, laboratory testing, including blood count, serologic, biochemical, cell subpopulation, cytokines and CT scan. The results revealed that in the UC-MSC group, there was a reduction in the levels of ferritin, IL-6 and MCP1- CCL2 on the fourteen day. In the second month, a decrease in the levels of reactive C-protein, D-dimer and neutrophils and an increase in the numbers of TCD3, TCD4 and NK lymphocytes were observed. A decrease in extension of lung damage was observed at the fourth month. The improvement in all these parameters was maintained until the end of patient follow-up.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83084https://www.arca.fiocruz.br/bitstream/icict/52571/1/license.txt783568c2893d2e25a99990b126be1772MD51ORIGINALs13287-022-0279OK.pdfs13287-022-0279OK.pdfapplication/pdf5220942https://www.arca.fiocruz.br/bitstream/icict/52571/2/s13287-022-0279OK.pdf616fce65779510c1e18ff103ef3350d8MD52icict/525712022-05-06 15:48:27.358oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-05-06T18:48:27Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial |
| title |
Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial |
| spellingShingle |
Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial Rebelatto, Carmen Lúcia Kuniyoshi COVID-19 Postacute sequelae Terapia Celular Mesenchymal Stem Cells Subacute Care Cell- and Tissue-Based Therapy Células Madre Mesenquimatosas Atención Subaguda Tratamiento Basado en Trasplante de Células y Tejidos Cellules souches mésenchymateuses Soins de suite Thérapie cellulaire et tissulaire Células-Tronco Mesenquimais Cuidados Semi-Intensivos Terapia Baseada em Transplante de Células e Tecidos |
| title_short |
Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial |
| title_full |
Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial |
| title_fullStr |
Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial |
| title_full_unstemmed |
Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial |
| title_sort |
Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial |
| author |
Rebelatto, Carmen Lúcia Kuniyoshi |
| author_facet |
Rebelatto, Carmen Lúcia Kuniyoshi Senegaglia, Alexandra Cristina Franck, Claudio Luciano Daga, Debora Regina Shigunov, Patrícia Stimamiglio, Marco Augusto Marsaro, Daniela Boscaro Schaidt, Bruna Micosky, Andressa Azambuja, Ana Paula de Leitão, Cleverson Alex Petterle, Ricardo Rasmussen Jamur, Valderez Ravaglio Vaz, Isadora May Mallmann, Antônio Paulo Carraro Junior, Hipólito Ditzel, Eduardo Brofman, Paulo Roberto Slud Correa, Alejandro |
| author_role |
author |
| author2 |
Senegaglia, Alexandra Cristina Franck, Claudio Luciano Daga, Debora Regina Shigunov, Patrícia Stimamiglio, Marco Augusto Marsaro, Daniela Boscaro Schaidt, Bruna Micosky, Andressa Azambuja, Ana Paula de Leitão, Cleverson Alex Petterle, Ricardo Rasmussen Jamur, Valderez Ravaglio Vaz, Isadora May Mallmann, Antônio Paulo Carraro Junior, Hipólito Ditzel, Eduardo Brofman, Paulo Roberto Slud Correa, Alejandro |
| author2_role |
author author author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Rebelatto, Carmen Lúcia Kuniyoshi Senegaglia, Alexandra Cristina Franck, Claudio Luciano Daga, Debora Regina Shigunov, Patrícia Stimamiglio, Marco Augusto Marsaro, Daniela Boscaro Schaidt, Bruna Micosky, Andressa Azambuja, Ana Paula de Leitão, Cleverson Alex Petterle, Ricardo Rasmussen Jamur, Valderez Ravaglio Vaz, Isadora May Mallmann, Antônio Paulo Carraro Junior, Hipólito Ditzel, Eduardo Brofman, Paulo Roberto Slud Correa, Alejandro |
| dc.subject.other.pt_BR.fl_str_mv |
COVID-19 Postacute sequelae Terapia Celular |
| topic |
COVID-19 Postacute sequelae Terapia Celular Mesenchymal Stem Cells Subacute Care Cell- and Tissue-Based Therapy Células Madre Mesenquimatosas Atención Subaguda Tratamiento Basado en Trasplante de Células y Tejidos Cellules souches mésenchymateuses Soins de suite Thérapie cellulaire et tissulaire Células-Tronco Mesenquimais Cuidados Semi-Intensivos Terapia Baseada em Transplante de Células e Tecidos |
| dc.subject.en.pt_BR.fl_str_mv |
Mesenchymal Stem Cells Subacute Care Cell- and Tissue-Based Therapy |
| dc.subject.es.pt_BR.fl_str_mv |
Células Madre Mesenquimatosas Atención Subaguda Tratamiento Basado en Trasplante de Células y Tejidos |
| dc.subject.fr.pt_BR.fl_str_mv |
Cellules souches mésenchymateuses Soins de suite Thérapie cellulaire et tissulaire |
| dc.subject.decs.pt_BR.fl_str_mv |
Células-Tronco Mesenquimais Cuidados Semi-Intensivos Terapia Baseada em Transplante de Células e Tecidos |
| description |
Pontificia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa. Rio de Janeiro, RJ, Brasil. |
| publishDate |
2022 |
| dc.date.accessioned.fl_str_mv |
2022-05-06T18:48:27Z |
| dc.date.available.fl_str_mv |
2022-05-06T18:48:27Z |
| dc.date.issued.fl_str_mv |
2022 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
REBELATTO, Carmen Lúcia Kuniyoshi et al. Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial. Stem Cell Research & Therapy, V. 13, n. 122, p. 1–22, 2022 |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/52571 |
| dc.identifier.issn.pt_BR.fl_str_mv |
1757-6512 |
| dc.identifier.doi.none.fl_str_mv |
10.1186/s13287-022-02796-1 |
| identifier_str_mv |
REBELATTO, Carmen Lúcia Kuniyoshi et al. Safety and long‑term improvement of mesenchymal stromal cell infusion in critically COVID‑19 patients: a randomized clinical trial. Stem Cell Research & Therapy, V. 13, n. 122, p. 1–22, 2022 1757-6512 10.1186/s13287-022-02796-1 |
| url |
https://www.arca.fiocruz.br/handle/icict/52571 |
| dc.language.iso.fl_str_mv |
por |
| language |
por |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
BMC |
| publisher.none.fl_str_mv |
BMC |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/52571/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/52571/2/s13287-022-0279OK.pdf |
| bitstream.checksum.fl_str_mv |
783568c2893d2e25a99990b126be1772 616fce65779510c1e18ff103ef3350d8 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1798324935913897984 |